Theravance Biopharma doses first patient in phase 2 Covid-19 trial with JAKi inhibitor TD-0903

Theravance Biopharma has dosed the first patient in the phase 2 study of lung-selective and nebulized Janus kinase inhibitor (JAKi) TD-0903 to treat hospitalised patients with acute lung injury (ALI) due to Covid-19.